Ingen Gears-Up to Introduce New Low-Flow Oxyview Infant Nasal Cannula to Infant and...

Ingen Gears-Up to Introduce New Low-Flow Oxyview Infant Nasal Cannula to Infant
and Neonatal Respiratory Markets

YUCAIPA, Calif., July 10, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc.
(Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8
Billion global Respiratory Markets for the growing aging population and emerging
markets for Home (DME), Hospital and Aviation Industries announced today that
the company will introduce the new infant and pediatric Oxyview Nasal Cannula in
August, 2009.

Oxygen is the most commonly used therapy in neonatal nurseries as an integral
part of respiratory support. The goal of oxygen therapy is to achieve adequate
delivery of oxygen to the tissue without creating oxygen toxicity. Oxygen must
have been given to newborn preterm babies more than any other medicinal product
in the past 60 years. In 2006, 4,140,419 babies were born in the U.S. Ingen
Technologies will introduce the first neonatal nasal cannula that includes the
new low-flow Oxyview oxygen flow meter with accuracy between 0-3 liters/minute.

The new Oxyview Infant Nasal Cannula is specially designed for the neonatal
market and includes an infant soft-tip insert and the Oxyview low-flow oxygen
meter that provides accurate readings between 0-3 liters/minute. "There are no
other oxygen flow meters in the market that work in-line with an infant nasal
cannula," stated Christopher Wirth, Chief Operations Officer.

The company has already invested in the manufacture of an additional 30,000
Oxyview Infant Nasal Cannulas, as a test market. These cannulas will be
available for sale in August, 2009. "We have introduced the new Oxyview Nasal
Cannula to our existing distribution, and have received orders for several
hundred of the new nasal cannulas since the introduction in June. We expect
sales to continue to increase, and will provide an accounting of sales in our
next quarterly report ending August 31, 2009," stated Thomas J. Neavitt, Chief
Financial Officer.

The company recognizes a potential $20,000,000 of annual revenue with the
neonatal respiratory market. The company will include this new cannula with the
advertising program designed with COPD Digest and Medco Forum. "Our OEM partner,
Neotech Products, Inc., specializes in the neonatal markets. I have personally
worked with Arnold Heyman, MD, founder of Neotech Products, and we will offer
this company distribution rights to the new product. We are also seeking larger
distributors to replace the smaller distributorships we currently have in
certain U.S. territories. We are now addressing the reorganization of our
distribution to meet the needs of the new Oxyview Adult and Infant Nasal
Cannula," stated Scott R. Sand, Chief Executive Officer and Chairman of the
Board.

http://fn.bmjjournals.com/cgi/content/abstract/92/2/F143

http://pediatrics.aappublications.org/cgi/content/abstract/82/4/527

http://www.healthline.com/galecontent/neonatal-respiratory-care

http://www.neotechproducts.com/

About Oxyview:

Oxyview is a proprietary medical device with U.S. issued patents that stands
alone in an increasing patient home oxygen therapy market while there are 23
million patients diagnosed with chronic obstructive pulmonary disease (COPD) in
the United States, according to the World Health Organization, and another 12
million patients that are undiagnosed in the U.S. COPD is the fifth leading
cause of death in the U.S. and there are 600 million COPD patients worldwide
where in most cases, COPD is either the first or second leading cause of death
in other countries. The majority of COPD patients require continued home oxygen
therapy, which includes all of the required equipment supplied by the home (DME)
provider. With the new regulations for oxygen reimbursement in the U.S., the
home (DME) providers need to cut costs to stay in business. Oxyview provides a
substantial savings as a result of decreasing the number of service calls for
the home (DME) provider. Oxyview is a pneumatic metering device that displays
oxygen flow near the patient. The Oxyview flow meter easily and quickly installs
on to the oxygen tubing nearest the patient where oxygen flow matters the most.
Without the Oxyview, patients cannot confirm oxygen flow, and as a result there
is an increase in anxiety and the patient calls the home (DME) provider with
concerns. Oxyview also allows the home (DME) provider to trouble-shoot other
equipment problems over the telephone which eliminates an on-site visit with the
patient. More important, the Oxyview provides the patient with more assurance
that they are receiving adequate and prescribed oxygen flow. The Oxyview cost
less than a single service call.

www.ingen-tech.com

Safe Harbor for Forward-Looking Statements:

This news release includes forward-looking statements. While these statements
are made to convey to the public the company's progress, business opportunities
and growth prospects, readers are cautioned that such forward-looking statements
represent management's opinion. Whereas management believes such representations
to be true and accurate based on information and data available to the company
at this time, actual results may differ materially from those described. The
company's operations and business prospects are always subject to risk and
uncertainties. Important factors that may cause actual results to differ are and
will be set forth in the company's periodic filings with the U.S. Securities and
Exchange Commission.

-0-
CONTACT: Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
www.INGEN-TECH.COM